PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases

Current Pharmaceutical Design

Volumn 17, Issue 34, 2011, Pages 3815-3822

  Shenker, Bruce J ^a   Ali, Hydar ^b   Boesze Battaglia, Kathleen ^c  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b Departments of Biochemistry Pathology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bacterial toxins; Cytolethal distending toxin; Glycerophosphates; Glycerosphingolipids; Gram negative pathogens; Pharmacology; Phosphatidic acids; Phosphatidylinositols

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FC RECEPTOR IIA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ANTIGEN BINDING; ASTHMA; BINDING AFFINITY; CELL ACTIVATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LONG TERM CARE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 83455238361     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798357926     Document Type: Review

References (81)

1. Kinet J. The essential role of mast cells in orchestrating inflammation. Immunological Reviews 2007; 217: 5-7.
2. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 2010; 17: 4981-90.
3. Rivera J, Olivera A. A current understanding of FcRI-dependent mast cell activation. Curr Allergy Asthma Rep 2008; 8: 14-20.
4. Ogawa Y, Grant A. Mediators of anaphylaxis. Immunol Allergy Clinics North America 2007; 27: 249-60.
5. Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition inflammation: toward tailored therapies for specific diseases. Bioessays 2010; 32: 185-96.
6. Deho L, Monticelli S. Human mast cells and mastocytosis: harnessing microRNA expression as a new approach to therapy. Arch Immunol Ther Exp 2010; 58: 279-86.
7. Abraham S, St. John A. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440-52.
8. 2+ mobilization and G protein usage on regulation of Toll-like receptor function in human and murine mast cells. Immunology 2006; 119: 412-20.
9. Casale TB, Stokes JR. Future forms of immunotherapy. Clin Rev Allergy Immunol 2011; 127: 8-15.
10. McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 2009; 27: 3544-52.
11. Firszt R, Kraft M. Pharmacotherapy of severe asthma. Curr Opin Pharmacol 2010; 10: 266-71.
12. Kaliner MA. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004; 4: 237-44.
13. Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Exp Opin Investig Drugs 2000; 9(1): 25-42.
14. Slater JE, Boltansky H, Kaliner M. Effect of an IgE-ricin A chain conjugate on rat skin histamine content. J Immunol 1988; 140(3): 807-11.
15. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 2002; 88: 152-61.
16. Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother 2004; 38: 1236-42.
17. Nadler MJ, Matthews SA, Turner H, Kinet JP. Signal transduction by the high-affinity immunoglobulin E receptor Fccoupling form to function. Advances in Immunology 2000; 76: 325-55.
18. Kraub M, Haucke V. Phosphoiositides: regulators of membrane traffic and protein function. FEBS Lett 2007; 581: 2105-11.
19. Sasaki T, Sasaki J, Sakai T, Takasuga S, Suzuki A. The physiology of phosphoinositides. Biol Pharm Bull 2007; 30(9): 1599-604.
20. Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 2008; 9: 99-111.
21. Abramson J, Pecht I. Regulation of the mast cell response to the type 1 Fc receptor. Immunol Rev 2007; 217: 231-54.
22. Tkaczyk C, Gilfillan AM. FcRI-dependent signaling pathways in human mast cells. Clin Immunol 2001; 99: 198-210.
23. Kuehn HS, Radinger M, Brown JM, et al. Btk-dependent Rac activation and actin rearrangement following FcRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci 2010; 123: 2576-85.
24. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD, Gilfillan AM. The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. J Immunol 2008; 181: 7706-12.
25. Willox I, Mirkina I, Westwick J, Ward S. Evidence for PI3Kdependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells. Mol Immunol 2010; 47: 2367-77.
26. Hochdorfer T, Kuhny M, Zorn C, et al. Activation of the PI3K pathway increases TLR-induced TNF-α and IL-6 but reduces IL-1 production in mast cells. Cell Signal 2011; 23: 866-75.
27. Tolarová J, Dráberová L, Heneberg P, Dráber P. Involvement of filamentous actin in setting the threshold for degranulation in mast cells. Eur J Immunol 2004; 34: 1627-36.
28. Volná P, Lebduška P, Dráberová L, et al. Negative regulation of mast cell signaling and function by the adaptor LAB/NTAL. J Exp Med 2004; 200: 1001-13.
29. 2+ signaling in mast cells by tyrosine-phosphorylated and unphosphorylated non-T cell activation linker. J Immunol 2007; 179: 5169-80.
30. Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcRI-mediated mast cell activation. Immunol Lett 2007; 113: 59-69.
31. Laffargue M, Calvez R, Finan P, et al. Phosphoinositide 3 kinase is an essential amplifier of mast cell function. Immunity 2002; 16: 441-51.
32. Nunomura S, Gon Y, Yoshimaru T, Kashiwakura J, Kawakami T, Ra C. FcRI β-chain ITAM amplifies PI3K-signaling to ensure synergistic degranulation response via FcεRI and adenosine receptors. Eur J Immunol 2010; 40: 1205-17.
33. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood 2007; 111: 4193-200.
34. Jolly PS, Bektas M, Olivera A, et al. Transactivation of sphingosine-1-phosphate receptors by FcRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004; 199: 959-70.
35. Lee MJ, Thangada S, Paik JH, et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell 2001; 8: 693-704.
36. Rivera J, Olivera R. Src family kinases and lipid mediators in control of allergic inflammation. Immunol Rev 2007; 217: 255-68.
37. Gilfillan AM, Tkaczyk C. Integrated signaling pathways for mastcell activation. Nat Rev Immunol 2006; 6: 218-30.
38. Kawakami T, Galli SJ. Regulation of mast cell and basophil function and survival by IgE. Nat Rev Immunol 2002; 2: 773-86.
39. Okayama Y, Kawakami T. Development, migration and survival of mast cells. Immunol Res 2006; 34: 97-115.
40. Ryan JJ, Kashyap M, Bailey D, et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 2007; 27: 15-32.
41. Bachelet I, Munitz A, Levi-Schaffer F. Abrogation of allergic reactons by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 2006; 117: 1314-20.
42. Furumoto Y, Brooks S, Olivera A, et al. Lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J Immunol 2006; 176: 5167-71.
43. Huber M, Kalesnikoff J, Reth M, Krystal G. The role of SHIP in mast cell degranulation and IgE-induced mast cell survival. Immunol Lett 2002; 82: 17-21.
44. Huber M, Helgason CD, Damen J, Liu L, Humphries RK, Krystal G. The src homology2-containing inositol phosphatase is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci USA 1998; 95: 11330-5.
45. Kim MS, Radinger M, Gilfillan AM. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 2008; 29: 493-501.
46. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
47. Ali K, Bilancio A, Thomas M, et al. Essential role for the p110δphosphoinositde 3-kinase in the allergic response. Nature 2004; 431: 1007-11.
48. Seminario MC, Wange RL. Signaling pathways of D3-phosphoinositide-binding kinases in T cells and their regulation by PTEN. Semin Immunol 2002; 14: 27-36.
49. Krystal G. Lipid phosphatases in the immune system. Semin Immunol 2000; 12: 397-403.
50. March ME, Ravichandran K. Regulation of the immune response by SHIP. Semin Immunol 2002; 14: 37-47.
51. Sly L, Rauh M, Kalesnikoff J, Buchse T, Krystal G. SHIP, SHIP2 and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 2003; 31: 1170-81.
52. Ong CJ, Ming-Lum A, Nodwell M, et al. Small molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 2011; 110: 1942-9.
53. Bohnacker T, Marone R, Collmann E, Calvez R, Hirsch E, Wymann MP. PI3K adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5) P3 pools in mast cells. Science Signaling 2009; 2: 1-12.
54. Endo D, Gon Y, Nunomura S, Yamashita K, Hashimoto S, Ra C. PI3Kγ differentially regulates FcRI-mediated degranulation and migration of mast cells by and toward antigen. Int Arch Allergy Immunol 2009; 149: 66-72.
55. Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leuk Biol 2005; 78: 1378-85.
56. Comayras C, Tasca C, Peres SY, Ducommun B, Oswald E, De Rycke J. Escherichia coli cytolethal distending toxin blocks the HeLa cell cycle at the G2/M transition by preventing cdc2 protein kinase dephosphorylation and activation. Infect Immun 1997; 65: 5088-95.
57. Okuda J, Fukumoto M, Takeda Y, Nishibuchi M. Examination of diarrheagenicity of cytolethal distending toxin: suckling mouse response to the products of the cdtABC genes of Shigella dysenteriae. Infect Immun 1997; 65: 428-33.
58. Okuda J, Kurazono H, Takeda Y. Distribution of the cytolethal distending toxin A gene (cdtA) among species of Shigella and Vibrio, and cloning and sequencing of the cdt gene from Shigella dysenteriae. Microbial Pathogen 1995; 18: 167-72.
59. Scott DA, Kaper JB. Cloning and sequencing of the genes encoding Escherichia coli cytolethal distending toxin. Infect Immun 1994;62(1): 244-51.
60. Pickett CL, Cottle DL, Pesci EC, Bikah G. Cloning, sequencing, and expression of the Escherichia coli cytolethal distending toxin genes. Infect Immun 1994; 62: 1046-51.
61. Mayer M, Bueno L, Hansen E, DiRienzo JM. Identification of a cytolethal distending toxin gene locus and features of a virulenceassociated region in Actinobacillus actinomycetemcomitans. Infect Immun 1999; 67: 1227-37.
62. Pickett CL, Whitehouse CA. The cytolethal distending toxin family. Trends Microbiol 1999; 7: 292-7.
63. Shenker BJ, Besack D, McKay TL, Pankoski L, Zekavat A, Demuth DR. Induction of cell cycle arrest in lymphocytes by Actinobacillus actinomycetemcomitans cytolethal distending toxin requires three subunits formaximum activity. J Immunol 2005; 174: 2228-34.
64. Boesze-Battaglia K, Besack D, McKay TL, et al. Cholesterol-rich membrane microdomains mediate cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin. Cell Microbiol 2006; 8: 823-36.
65. Shenker BJ, Demuth DR, Zekavat A. Exposure of lymphocytes to high doses of Actinoibacillus actinomycetemcomitans cytolethal distending toxin induces rapid onset of apoptosis-mediated DNA fragmentation. Infect Immun 2006; 74: 2080-92.
66. Shenker BJ, Dlakic M, Walker L, et al. A novel mode of action for a microbial-derived immunotoxin: the cytolethal distending toxin subunit B exhibits phosphatidylinositol (3,4,5) tri-phosphate phospatase activity. J Immunol 2007; 178: 5099-108.
67. Boesze-Battaglia K, Brown A, Walker L, et al. Cytolethal distending toxin-induced cell cycle arrest of lymphocytes is dependent upon recognition and binding to cholesterol. J Biol Chem 2009; 284: 10650-8.
68. Shenker BJ, McKay TL, Datar S, Miller M, Chowhan R, Demuth DR. Actinobacillus actinomycetemcomitans immunosuppressive protein is a member of the family of cytolethal distending toxins capable of causing a G2 arrest in human T cells. J Immunol 1999; 162: 4773-80.
69. Shenker BJ, Hoffmaster RH, McKay TL, Demuth DR. Expression of the cytolethal distending toxin (Cdt) operon in Actinobacillus actinoimycetemcomitans: evidence that the CdtB protein is responsible for G2 arrest of the cell cycle in human T-cells. J Immunol 2000; 165: 2612-18.
70. Shenker BJ, Hoffmaster RH, Zekavat A, Yamguchi N, Lally ET, Demuth DR. Induction of apoptosis in human T cells by Actinobacillus actinomycetemcomitans cytolethal distending toxin is a consequence of G2 arrest of the cell cycle. J Immunol 2001; 167: 435-41.
71. De Rycke J, Oswald E. Cytolethal distending toxin (CDT): a bacterial weapon to control host cell proliferaton? FEMS Microbiol Lett 2001; 203: 141-8.
72. Thelastam M, Frisan T. Cytolethal distending toxins. Rev Physiol Biochem Pharmacol 2004; 152: 111-33.
73. Nesic D, Hsu Y, Stebbins CE. Assembly and; function of a bacterial genotoxin. Nature 2004; 429: 429-33.
74. Elwell CA, Chao K, Patel K, Dreyfus LA. Escherichia coli CdtB Mediates Cytolethal Distending Toxin Cell cycle Arrest. Infect Immun 2001; 69: 3418-22.
75. Lara-Tejero M, Galan JE. CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. Infect Immun 2001; 69: 4358-65.
76. Shenker B, Boesze-Battaglia K, Zekavat A, Walker L, Besack D, Ali H. Inhibition of mast cell degranulation by a chimeric toxin containing a novel phosphatidylinositol-3,4,5-triphosphate phosphatase. Mol Immunol 2010; 48: 203-10.
77. Horn S, Endl E, Fehse B, Weck MM, Mayr GW, Jucker M. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/ GSK-3 signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004; 18: 1839-49.
78. Seminario MC, Wange RL. Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial. Immunol Cell Biol 2003; 192: 80-97.
79. Seminario MC, Precht P, Wersto RP, Gorospe M, Wange RL. PTEN expression in PTEN-null leukeamic T cell lines leads to reduced proliferation via slowed cell cycle progression. Oncogene 2003; 22: 8195-204.
80. Ma K, Cheung S, Marshall AD, V. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal 2011; 20: 684-94.
81. Scheid M, Huber M, Damen J, et al. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for proteins kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylaton at Ser-473. J Biol Chem 2002; 277: 9027-35.